Pelc A, Castan J P
IMS Health Economics, Paris, France.
Pharmacoeconomics. 1994;6 Suppl 1:28-35. doi: 10.2165/00019053-199400061-00009.
In this article, we review the current French price reimbursement scheme and how this scheme is affected by a new decree published in 1993, or will be affected by this decision already announced but not yet implemented. France has been perceived as a pioneering country regarding the attitude of the Health Authority towards pharmacoeconomics. Here, we describe the present status afforded such studies in the price reimbursement scheme. Finally, we discuss the possible impact of the national agreement between physicians and statutory Health Funds on the pharmaceutical industry in France.
在本文中，我们回顾了当前法国的价格报销方案，以及该方案如何受到1993年发布的一项新法令的影响，或者将如何受到已宣布但尚未实施的这一决定的影响。法国在卫生当局对药物经济学的态度方面被视为一个先驱国家。在此，我们描述了此类研究在价格报销方案中的现状。最后，我们讨论了医生与法定健康基金之间的全国性协议对法国制药行业可能产生的影响。
